Moderna, Inc. (NASDAQ: MRNA) received its estimate for the present quarter’s sales. Brokerages at Wall Street issued an estimate of $1.97B for the company.
Stock Overview Of MRNA
Estimates were issued by six analysts for MRNA stock. The lowest and the largest predictions stand at $1.71B and $2.47B. For last year’s same quarter, the company had reported $8.39M sales. The latest earnings report is scheduled to be made on 6th May, Thursday before the day opens.
The latest earnings of the company were issued on 25th February, Thursday. An EPS of $0.69 was reported which overshot the estimated $0.25. The firm a negative 28.11% return equity and a 242.73% negative net margin.
Several research analysts have issued their reports on MRNA stock. Bank of America reiterated their rating of “sell” while setting a target price of $140 on 26th February, Friday. Brookline Capital Management increased their target price to $205 from $180 while issuing a rating of “buy” on 4th March, Thursday. Oppenheimer increased their target price to $206 from $178 while issuing a rating of “outperform” on 1st February. Barclays increased their target price to $178 from $169 on 26th February, Friday. Finally, Zacks Investment Research decreased the rating to “hold” from “buy” while setting a price target of $170 on 20th April, Tuesday.
On Monday, the stock opened with a value of $178.82. The moving averages for the stock over 50 days stand at $147.74 while for 200 days it stands at $130.59. The market capitalization value of the stock stands at $71.62B with a 1.73 beta. The lowest and highest of the stock over a year stands at $46.13 and $189.26 respectively.
Tal Zvi Zaks, an insider, sold off 10,034 MRNA shares on 15th March, Monday at a $140.68 average price per share. Juan Andres, an insider, sold off 5000 shares on 10th March, Wednesday at a $133.24 average price per share.
